TP53 and cancer: In other words, the wt and mutant p53 are concurrently expressed in the cells of patients who are in the early stage cancer cells with a somatic mutation in one TP53 allele or carry the germline mutation; therefore, heterotetramers with wt and mutant p53 proteins are formed, which are able to induce prion properties of aggregated p53, and these heterotetramers are unable to bind to its genetic targets [29,90,91].